Literature DB >> 1996309

Activated protooncogenes in human lung tumors from smokers.

S H Reynolds1, C K Anna, K C Brown, J S Wiest, E J Beattie, R W Pero, J D Iglehart, M W Anderson.   

Abstract

Fourteen primary human lung tumor DNAs from smokers were analyzed for transforming activity by two DNA transfection assays. Activated protooncogenes were detected in 3 of 11 tumor DNAs by the NIH 3T3 focus assay, whereas activated protooncogenes were detected in 11 of 13 tumor DNAs by the NIH 3T3 cotransfection-nude mouse tumorigenicity assay. K- or NRAS genes activated by point mutation at codons 12 or 61 were detected in a large cell carcinoma, a squamous cell carcinoma, and 5 adenocarcinomas. An HRAS oncogene activated by a different mechanism was detected in an epidermoid carcinoma. One adenocarcinoma was found to contain an activated RAF gene. Two unidentified transforming genes were detected in a squamous cell carcinoma DNA and two adenocarcinoma DNAs. Eight of 10 lung adenocarcinomas that had formed metastases at the time of surgery were found to contain RAS oncogenes. No significant increase in metastasis was observed in the lung adenocarcinomas that contained one or more 6-kilobase EcoRI alleles of the LMYC gene. Overall, 12 of 14 (86%) of the lung tumor DNAs from smokers were found to contain activated protooncogenes. RAS oncogenes appear to play a role in the development of metastases in lung adenocarcinomas.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1996309      PMCID: PMC50961          DOI: 10.1073/pnas.88.4.1085

Source DB:  PubMed          Journal:  Proc Natl Acad Sci U S A        ISSN: 0027-8424            Impact factor:   11.205


  38 in total

1.  A study of the aetiology of carcinoma of the lung.

Authors:  R DOLL; A B HILL
Journal:  Br Med J       Date:  1952-12-13

2.  Primer-directed enzymatic amplification of DNA with a thermostable DNA polymerase.

Authors:  R K Saiki; D H Gelfand; S Stoffel; S J Scharf; R Higuchi; G T Horn; K B Mullis; H A Erlich
Journal:  Science       Date:  1988-01-29       Impact factor: 47.728

3.  Identification of the principal promoter sequence of the c-H-ras transforming oncogene: deletion analysis of the 5'-flanking region by focus formation assay.

Authors:  H Honkawa; W Masahashi; S Hashimoto; T Hashimoto-Gotoh
Journal:  Mol Cell Biol       Date:  1987-08       Impact factor: 4.272

Review 4.  The chemical composition of tobacco and tobacco smoke.

Authors:  R L Stedman
Journal:  Chem Rev       Date:  1968-04       Impact factor: 60.622

5.  H-ras p21 and the metastatic phenotype.

Authors:  L A Liotta
Journal:  J Natl Cancer Inst       Date:  1988-06-01       Impact factor: 13.506

Review 6.  Cellular oncogenes and retroviruses.

Authors:  J M Bishop
Journal:  Annu Rev Biochem       Date:  1983       Impact factor: 23.643

7.  KRAS codon 12 mutations occur very frequently in pancreatic adenocarcinomas.

Authors:  V T Smit; A J Boot; A M Smits; G J Fleuren; C J Cornelisse; J L Bos
Journal:  Nucleic Acids Res       Date:  1988-08-25       Impact factor: 16.971

8.  Mutational activation of the K-ras oncogene. A possible pathogenetic factor in adenocarcinoma of the lung.

Authors:  S Rodenhuis; M L van de Wetering; W J Mooi; S G Evers; N van Zandwijk; J L Bos
Journal:  N Engl J Med       Date:  1987-10-08       Impact factor: 91.245

9.  Most human carcinomas of the exocrine pancreas contain mutant c-K-ras genes.

Authors:  C Almoguera; D Shibata; K Forrester; J Martin; N Arnheim; M Perucho
Journal:  Cell       Date:  1988-05-20       Impact factor: 41.582

10.  Close correlation between restriction fragment length polymorphism of the L-MYC gene and metastasis of human lung cancer to the lymph nodes and other organs.

Authors:  K Kawashima; H Shikama; K Imoto; M Izawa; T Naruke; K Okabayashi; S Nishimura
Journal:  Proc Natl Acad Sci U S A       Date:  1988-04       Impact factor: 11.205

View more
  16 in total

Review 1.  Farnesyl protein transferase inhibitors and other therapies targeting the Ras signal transduction pathway.

Authors:  D W End
Journal:  Invest New Drugs       Date:  1999       Impact factor: 3.850

2.  RASSF1A promoter methylation and Kras2 mutations in non small cell lung cancer.

Authors:  Jie Li; Zhongqiu Zhang; Zunyan Dai; Anthony P Popkie; Christoph Plass; Carl Morrison; Yian Wang; Ming You
Journal:  Neoplasia       Date:  2003 Jul-Aug       Impact factor: 5.715

Review 3.  Pulmonary adenocarcinoma: a renewed entity in 2011.

Authors:  Humam Kadara; Mohamed Kabbout; Ignacio I Wistuba
Journal:  Respirology       Date:  2012-01       Impact factor: 6.424

4.  Conditional expression of the mutant Ki-rasG12C allele results in formation of benign lung adenomas: development of a novel mouse lung tumor model.

Authors:  Heather S Floyd; Charles L Farnsworth; Nancy D Kock; Melissa C Mizesko; Joy L Little; Stephanie T Dance; Jeff Everitt; Jay Tichelaar; Jeffrey A Whitsett; Mark Steven Miller
Journal:  Carcinogenesis       Date:  2005-07-28       Impact factor: 4.944

5.  Growth inhibitory effect of wild-type Kras2 gene on a colonic adenocarcinoma cell line.

Authors:  Hong Li; Hou-Fa Cao; Jun Wan; Yuan Li; Mei-Ling Zhu; Po Zhao
Journal:  World J Gastroenterol       Date:  2007-02-14       Impact factor: 5.742

6.  The genomics of lung adenocarcinoma: opportunities for targeted therapies.

Authors:  Heidi Greulich
Journal:  Genes Cancer       Date:  2010-12

7.  Parental bias of Ki-ras oncogenes detected in lung tumors from mouse hybrids.

Authors:  M You; Y Wang; G Stoner; L You; R Maronpot; S H Reynolds; M Anderson
Journal:  Proc Natl Acad Sci U S A       Date:  1992-07-01       Impact factor: 11.205

8.  Assignment of a locus for mouse lung tumor susceptibility to proximal chromosome 19.

Authors:  T R Devereux; R W Wiseman; N Kaplan; S Garren; J F Foley; C M White; C Anna; M A Watson; A Patel; S Jarchow
Journal:  Mamm Genome       Date:  1994-12       Impact factor: 2.957

9.  Mutational activation of the MAP3K8 protooncogene in lung cancer.

Authors:  Adam Michael Clark; Steven H Reynolds; Marshall Anderson; Jonathan S Wiest
Journal:  Genes Chromosomes Cancer       Date:  2004-10       Impact factor: 5.006

10.  Variations in the vascular endothelial growth factor pathway predict pulmonary complications.

Authors:  Jae Y Kim; Michelle A T Hildebrandt; Xia Pu; Yuanqing Ye; Arlene M Correa; Ara A Vaporciyan; Xifeng Wu; Jack A Roth
Journal:  Ann Thorac Surg       Date:  2012-07-12       Impact factor: 4.330

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.